Special Issue

The Role of Extracellular Vesicles in Hepatic, Pancreatic and Biliary Diseases

Message from the Guest Editors

This Special Issue focuses on the role of extracellular vesicles (EVs) in regulating pathogenic processes in the liver, pancreas or biliary system. EVs, such as exosomes and microvesicles, are produced by multiple cell types and carry a complex molecular payload comprising proteins, mRNAs and microRNAs that reflect the varied phenotypic statuses of the producer cells. We invite contributors to submit original research and review articles discussing any aspect of the EVs involved in hepatic, pancreatic or biliary diseases, such as primary tissue injury, inflammation, fibrosis and cancer. Researchers should limit the focus of their studies of diabetes to the EV biology of pancreatic islet dysfunction. Potential topics of interest regarding the role of EVs in hepatic, pancreatic or biliary diseases include, but are not limited to, the following research

- Mechanisms that alter the production of EVs during disease;
- Mechanisms of EV-mediated pathogenesis;
- Analysis and functional relevance of EV molecular cargo;
- EV-based disease diagnosis or prognosis;
- EV-mediated therapy.

Guest Editors

Dr. David R. Brigstock

- 1. Center for Clinical and Translational Research; the Research Institute at Nationwide Children's Hospital, Columbus, OH, USA
- 2. Department of Surgery, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.

Dr. Xinlei Li

Center for Clinical and Translational Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA

Deadline for manuscript submissions

closed (31 January 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/177687

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).